|30.94||+2.23||+7.77%||Vol 1.42M||1Y Perf 211.05%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||-0.19 -0.61%|
|Target Price||20.38||Analyst Rating||Strong Buy 1.30|
|Potential %||-34.13||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/100/50||Value Ranking||★★ 45.82|
|Insiders Value % 3/6/12 mo.||-/100/-16||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/36||Income Ranking||— -|
|Price Range Ratio 52W %||81.76||Earnings Rating||—|
|Market Cap||5.38B||Earnings Date||2nd Nov 2023|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.86|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.12M|
|Avg. Monthly Volume||1.19M|
|Avg. Quarterly Volume||1.37M|
BridgeBio Pharma Inc. (NASDAQ: BBIO) stock closed at 30.94 per share at the end of the most recent trading day (a 7.77% change compared to the prior day closing price) with a volume of 1.42M shares and market capitalization of 5.38B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 396 people. BridgeBio Pharma Inc. CEO is Neil Kumar.
The one-year performance of BridgeBio Pharma Inc. stock is 211.05%, while year-to-date (YTD) performance is 306.04%. BBIO stock has a five-year performance of %. Its 52-week range is between 6.64 and 36.36, which gives BBIO stock a 52-week price range ratio of 81.76%
BridgeBio Pharma Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 123.68, a price-to-sale (PS) ratio of 14.70, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -70.57%, a ROC of -63.99% and a ROE of 55.51%. The company’s profit margin is -%, its EBITDA margin is -467.10%, and its revenue ttm is $75.78 Million , which makes it $0.51 revenue per share.
Of the last four earnings reports from BridgeBio Pharma Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.86 for the next earnings report. BridgeBio Pharma Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for BridgeBio Pharma Inc. is Strong Buy (1.3), with a target price of $20.38, which is -34.13% compared to the current price. The earnings rating for BridgeBio Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BridgeBio Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BridgeBio Pharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.37, ATR14 : 1.55, CCI20 : 110.89, Chaikin Money Flow : 0.12, MACD : 0.76, Money Flow Index : 56.20, ROC : 12.43, RSI : 63.08, STOCH (14,3) : 99.17, STOCH RSI : 1.00, UO : 60.63, Williams %R : -0.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BridgeBio Pharma Inc. in the last 12-months were: Brian C. Stephenson (Option Excercise at a value of $0), Brian C. Stephenson (Sold 157 514 shares of value $1 793 976 ), Charles J. Homcy (Option Excercise at a value of $0), Homcy Charles (Sold 0 shares of value $0 ), Kumar Neil (Sold 0 shares of value $0 ), Kumar Neil (Sold 51 552 shares of value $1 500 253 ), Neil Kumar (Option Excercise at a value of $0), Neil Kumar (Sold 364 798 shares of value $1 889 770 ), Randal W. Scott (Sold 2 500 shares of value $75 000 ), Richard H. Scheller (Option Excercise at a value of $0), Stephenson Brian (Sold 0 shares of value $0 ), Stephenson Brian (Sold 392 710 shares of value $5 481 322 ), Valantine Hannah (Sold 0 shares of value $-24 632 ), Valantine Hannah (Sold 2 915 shares of value $87 450 )
Wed, 11 Oct 2023 06:30 GMT Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Syndax Pharmaceuticals (SNDX)- TipRanks. All rights reserved.
Tue, 29 Aug 2023 12:31 GMT Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Alkermes (ALKS)- TipRanks. All rights reserved.
Mon, 17 Jul 2023 13:25 GMT BridgeBio Pharma (BBIO) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Wed, 05 Jul 2023 16:35 GMT BridgeBio Pharma (BBIO) Gets a Buy from Mizuho Securities- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.